Beta
ManageSearchChatDiscover
179783

Effectiveness and Dose of Carvedilol Therapy In Children with Dilated Cardiomyopathy: A Prospective Randomized Double-Blinded Trial

Article

Last updated: 04 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

Background: The efficacy and safety of the beta blocker carvedilol in pediatric patients with chronic heart failure (CHF) has not been fully established till now.
Aim of the Work: To assess the role of carvedilol in the treatment of children with dilated cardiomyopathy, to demonstrate its efficacy, tolerability and determine the least effective dose.
Patients and Methods: We conducted a double-blind, placebo-controlled study of 53 children with dilated cardiomyopathy. Patients were randomly assigned to receive either placebo (26 patients) or carvedilol (27 patients) added to the standard CHF therapy that consists of angiotensin-converting-enzyme inhibitor and diuretics. The carvedilol group was further subdivided into 2 groups according to the received dose of carvedilol. Subgroup I (11 cases) received carvedilol dose of 0.01-0.09 mg/kg/day and subgroup II (16 cases) received carvedilol with dose increments every 2 weeks from 0.01-0.2 mg/kg/day. All patients were followed up for four months after reaching the target dose.
Results: The end results of the study showed that there was a significant improvement in Ross heart failure class, fractional shortening (FS), left ventricle end systolic dimension (LVESD) and left ventricle end diastolic dimension (LVEDD) in patients of the study group which was not achieved in the control group. On the other hand there was no statistically significant difference between sub groups I and II regarding the end point. Carvidolol was well tolerated, with no side effects or drug interaction reported.
Conclusion: Addition of carvedilol to standard anti-failure therapy is of beneficial effect and is well tolerated in children with CHF on top of DCM.  There may be no need for carvedilol dose up- titration at least for the first months of treatment.

DOI

10.21608/cupsj.2021.64625.1015

Keywords

Carvedilol, Heart failure, cardiomyopathy, Pediatric

Authors

First Name

Zeinab

Last Name

Selim

MiddleName

S.

Affiliation

Department of Pediatrics, Faculty of Medicine, Cairo University, Egypt.

Email

zeinabseliem14@yahoo.com

City

Cairo

Orcid

-

First Name

Sonia

Last Name

El-Saiedi

MiddleName

A.

Affiliation

Department of Pediatrics, Faculty of Medicine, Cairo University, Egypt.

Email

myheartclinic@windowslive.com

City

Cairo

Orcid

0000-0001-6992-4242

First Name

Reem

Last Name

Esmail

MiddleName

I.

Affiliation

Department of Pediatrics, Faculty of Medicine, Cairo University, Egypt.

Email

esmail_reem@yahoo.com

City

Cairo

Orcid

-

First Name

Rania

Last Name

El Kaffas

MiddleName

M. H.

Affiliation

Department of Pediatrics, Faculty of Medicine, Cairo University, Egypt.

Email

raniaelkaffas@yahoo.com

City

Giza

Orcid

-

First Name

Mohamed

Last Name

Meabed

MiddleName

-

Affiliation

Department of Pediatrics, Faculty of Medicine, Beni-Suef University, Egypt.

Email

m1hmeabed2@yahoo.com

City

Beni-Suef

Orcid

-

First Name

Baher

Last Name

Hanna

MiddleName

M.

Affiliation

Department of Pediatrics, Faculty of Medicine, Cairo University, Egypt.

Email

baherhanna@gmail.com

City

Cairo

Orcid

0000-0001-5252-8403

Volume

1

Article Issue

2

Related Issue

25899

Issue Date

2021-07-01

Receive Date

2021-02-22

Publish Date

2021-07-01

Page Start

62

Page End

70

Print ISSN

2805-279X

Online ISSN

2682-3985

Article File

CUPSJ_Volume 1_Issue 2_Pages 62-70.pdf

PDF . 783.7kB

Link

https://cupsj.journals.ekb.eg/article_179783.html

Detail API

https://cupsj.journals.ekb.eg/service?article_code=179783

Order

2

Type

Original Research

Type Code

1,229

Publication Type

Journal

Publication Title

Pediatric Sciences Journal

Publication Link

https://cupsj.journals.ekb.eg/

MainTitle

Effectiveness and Dose of Carvedilol Therapy In Children with Dilated Cardiomyopathy: A Prospective Randomized Double-Blinded Trial

Details

Type

Article

Created At

22 Jan 2023